Neridronate in bone marrow edema syndrome. Efficacy and safety of two therapeutic regimens

• Egile Nagusiak: Alfredomaria Lurati (Egilea), Antonella Laria (Egilea), Paola Faggioli (Egilea), Antonio Tamburello (Egilea), Laura Castelnovo (Egilea), Antonino Mazzone (Egilea)
• Formatua: Liburua
• Argitaratua: Verduci Editore, 2020-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The bone marrow edema syndrome (BMES) is a severely disabling pain syndrome without a definite treatment and refers to transient clinical conditions with unknown pathogenic mechanism, such as transient osteoporosis of the hip, regional migratory osteoporosis, and reflex sympathetic dystrophy. Magnet...